Intestinal helminthiasis
diseaseOn this page
Also known as intestine parasitic helminthiasis infectious disease
Summary
Intestinal helminthiasis (MONDO:0024271) is a disease and 6 clinical trials. Top therapeutic interventions include albendazole, ascorbic acid, and praziquantel. A subtype of helminthiasis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 6
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | intestinal helminthiasis |
| Mondo ID | MONDO:0024271 |
| MeSH | C531698 |
| SNOMED CT | 26249004 |
| UMLS | C0348287 |
| MedGen | 87591 |
| Anatomy (UBERON) | UBERON:0000160 |
| Is cancer (heuristic) | no |
Also known as: intestine parasitic helminthiasis infectious disease
Disease family
This is a subtype of helminthiasis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › parasitic infectious disease › helminthiasis › intestinal helminthiasis
Related subtypes (21): acanthocephaliasis, heterophyiasis, metagonimiasis, fascioliasis, fasciolopsiasis, monieziasis, clonorchiasis, dicrocoeliasis, echinostomiasis, fascioloidiasis, gnathomiasis, hymenolepiasis, necatoriasis, Nematoda infectious disease, opisthorchiasis, paragonimiasis, trichostrongyloidiasis, schistosomiasis, filariasis, angiostrongyliasis, Cestode infectious disease
Subtypes (3): taeniasis, intestinal schistosomiasis, anisakiasis
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 6.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 4 |
| PHASE4 | 1 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT02597556 | PHASE4 | WITHDRAWN | The Impact of Anthelmintic Treatment on the Incidence of Diarrheal Disease in Vietnamese School Children |
| NCT01640626 | PHASE1 | COMPLETED | Impact of Health Education on School Children |
| NCT01541631 | Not specified | UNKNOWN | A Study of Co-infections of HIV-1 and Schistosoma Mansoni and Its Impact on Praziquantel Treatment Outcomes |
| NCT01658774 | Not specified | COMPLETED | Impact of Repeated Anthelmintic Treatment on the Risk of Malaria in Kenyan School Children |
| NCT02399683 | Not specified | COMPLETED | Immune Modulation From Trichuris Trichiura |
| NCT03079700 | Not specified | COMPLETED | Immune Modulation From Trichuris Suis |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| ALBENDAZOLE | 4 | 3 |
| ASCORBIC ACID | 4 | 1 |
| PRAZIQUANTEL | 4 | 1 |
| CHEMBL3264245 | 0 | 1 |
Related Atlas pages
- Drugs: Albendazole, Ascorbic Acid, Praziquantel